Plasma and platelet clusterin ratio is altered in Alzheimer's disease patients with distinct neuropsychiatric symptoms: Findings from a pilot study

International Journal of Geriatric Psychiatry

Volumn 30, Issue 4, 2015, Pages 368-375

  Mukaetova Ladinska, Elizabeta B ^a   Abdel All, Zeinab ^a   Andrade, Joana ^b   Alves Da Silva, Joaquim ^c   O'Brien, John T ^a,d   Kalaria, Raj N ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF LISBON   (Portugal)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alzheimer's disease; behaviour; clusterin; dementia; plasma; platelet

Indexed keywords

CLUSTERIN; BIOLOGICAL MARKER;

AGED; AGITATION; ALZHEIMER DISEASE; APATHY; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DELUSION; DEPRESSION; FEMALE; HALLUCINATION; HUMAN; IRRITABILITY; MALE; PILOT STUDY; PLASMA; RISK; SYMPTOMATOLOGY; THROMBOCYTE; BLOOD; METABOLISM; MIDDLE AGED; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; BLOOD PLATELETS; CLUSTERIN; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PLASMA; SENSITIVITY AND SPECIFICITY;

EID: 84924160425     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4145     Document Type: Article

References (60)

1. Ahmed I, Ranney M, Craven RJ,. 2006. Clusterin is induced by cancer chemotherapy and suppresses histone deacetylase inhibitor-induced apoptosis in breast cancer. Proceedings of the 97th Annual Meeting of the American Association for Cancer Research; 2006 April 1-5; Washington, DC. Philadelphia (PA): AACR. Abstract B22.
2. Alexopoulos GA, Abrams RC, Young RC, et al,. 1988. Cornell Scale for Depression in Dementia. Biol Psychiatry 23: 271-284.
3. Baig S, Palmer LE, Owen MJ, et al,. 2012. Clusterin mRNA and protein in Alzheimer's disease. J Alzheimers Dis 28: 337-344.
4. Barral S, Bird T, Goate A, et al,. 2012. Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memory. Neurology 78: 1464-1471.
5. Bettens K, Brouwers N, Engelborghs S, et al,. 2012. Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegener 7: 3.
6. Braskie MN, Jahanshad N, Stein JL, et al,. 2011. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci 31: 6764-6770.
7. Brodaty H, Heffernan M, Draper B, et al,. 2012. Neuropsychiatric symptoms in older people with and without cognitive impairment. J Alzheimers Dis 31: 411-420.
8. Chen J, Wang M, Turko IV,. 2012a. Mass spectrometry quantification of clusterin in the human brain. Mol Neurodegener 7: 41.
9. Chen LH, Kao PY, Fan YH, et al,. 2012b. Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer's disease in a southern Chinese population. Neurobiol Aging 33: 210.e1-7.
10. Chibnik LB, Shulman JM, Leurgans SE, et al,. 2011. CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol 69: 560-569.
11. Colantonio DA, Dunkinson C, Bovenkamp DE, et al,. 2005. Effective removal of albumin from serum. Proteomics 5: 3831-3835.
12. Cummings JL, Mega M, Gray K, et al,. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314.
13. Dubois B, Feldman HH, Jacova C, et al,. 2007. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734-746.
14. Ferrari R, Moreno JH, Minhajuddin AT, et al,. 2012. Implication of common and disease specific variants in CLU, CR1, and PICALM. Neurobiol Aging 33: 1846.e7-18.
15. Gallagher D, Coen R, Kilroy D, et al,. 2011. Anxiety and behavioural disturbance as markers of prodromal Alzheimer's disease in patients with mild cognitive impairment. Int J Geriatr Psychiatry 26: 166-172.
16. García-Peña C, Wagner FA, Sánchez-García S, et al,. 2013. Late-life depressive symptoms: prediction models of change. J Affect Disord 150: 886-894.
17. Girard FP, Byrne J, Downes M, et al,. 2010. Detecting soluble clusterin in in-vitro and in-vivo models of prostate cancer. Neoplasma 57: 488-493.
18. Gu H, Wei X, Chen S, et al,. 2011. Association of clusterin gene polymorphisms with late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 32: 198-201.
19. Harold D, Abraham R, Hollingworth P, et al,. 2009. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41: 1088-1093.
20. Hopson DK, Niles AC, Murray PR,. 1992. Comparison of the Vitek Immunodiagnostic Assay System with three immunoassay systems for detection of cytomegalovirus-specific immunoglobulin G. J Clin Microbiol 30: 2893-2895.
21. Hwang TJ, Masterman DL, Ortiz F, et al,. 2004. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord 18: 17-21.
22. IJsselstijn L, Dekker LJ, Koudstaal PJ, et al,. 2011. Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. J Proteome Res 10: 2006-2010.
23. Ishii S, Weintraub N, Mervis JR,. 2009. Apathy: a common psychiatric syndrome in the elderly. J Am Med Dir Assoc 10: 381-393.
24. Jun G, Naj AC, Beecham GW, et al,. 2010. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 67: 1473-1478.
25. Karch CM, Jeng AT, Nowotny P, et al,. 2012. Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. PLoS One 7: e50976.
26. Katona C,. 1996. Managing depression in older people. Adv Psychiatr Treatment 2: 178-185.
27. Klimkowicz-Mrowiec A, Sado M, Dziubek A, et al,. 2013. Lack of association of CR1, PICALM and CLU gene polymorphisms with Alzheimer disease in a Polish population. Neurol Neurochir Pol 47: 157-160.
28. Komatsu M, Shibata N, Kuerban B, et al,. 2011. Genetic association between clusterin polymorphisms and Alzheimer's disease in a Japanese population. Psychogeriatrics 11: 14-18.
29. Lambert JC, Heath S, Even G, et al,. 2009. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41: 1094-1099.
30. Lancaster TM, Baird A, Wolf C, et al,. 2011. Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene. Eur Neuropsychopharmacol 21: 880-884.
31. Leroi I, Pantula H, McDonald K, et al,. 2012. Neuropsychiatric symptoms in Parkinson's disease with mild cognitive impairment and dementia. Parkinsons Dis 2012: 308097.
32. McKhann GM, Knopman DS, Chertkow H, et al,. 2011. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269.
33. Michels A, Multhammer M, Zintl M, et al,. 2012. Association of apolipoprotein E ε4 (ApoE ε4) homozygosity with psychiatric behavioral symptoms. J Alzheimers Dis 28: 25-32.
34. Muck-Seler D, Pivac N, Mustapic M, et al,. 2004. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Res 127: 217-226.
35. Mukaetova-Ladinska EB, Abdel-All Z, Dodds S, et al,. 2012. Platelet immunoglobulin and amyloid precursor protein as potential peripheral biomarkers for Alzheimer's disease: findings from a pilot study. Age Ageing 41: 408-412.
36. Mullan GM, McEneny J, Fuchs M, et al,. 2013. Plasma clusterin levels and the rs11136000 genotype in individuals with mild cognitive impairment and Alzheimer's disease. Curr Alzheimer Res 10: 973-978.
37. Narayan P, Meehan S, Carver JA, et al,. 2012. Amyloid-β oligomers are sequestered by both intracellular and extracellular chaperones. Biochemistry 51: 9270-9276.
38. Nuutinen T, Suuronen T, Kauppinen A, et al,. 2010. Valproic acid stimulates clusterin expression in human astrocytes: implications for Alzheimer's disease. Neurosci Lett 475: 64-68
39. Nuutinen T, Suuronen T, Kyrylenko S, et al,. 2005. Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells. Neurochem Int 47: 528-538.
40. Roth M, Tym E, Mountjoy CQ, et al,. 1986. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149: 698-709.
41. Rozek W, Ricardo-Dukelow M, Holloway S, et al,. 2007. Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res 6: 4189-4199.
42. Schrijvers EM, Koudstaal PJ, Hofman A, et al,. 2011. Plasma clusterin and the risk of Alzheimer disease. JAMA 305: 1322-1326.
43. Schürmann B, Wiese B, Bickel H, et al,. 2011. Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis 25: 421-424
44. Silajdžic E, Minthon L, Björkqvist M, et al,. 2012. No diagnostic value of plasma clusterin in Alzheimer's disease. PLoS One 7: e50237.
45. Somme JH, Fernández-Martínez M, Molano A, et al,. 2013. Neuropsychiatric symptoms in amnestic mild cognitive impairment: increased risk and faster progression to dementia. Curr Alzheimer Res 10: 86-94.
46. Song F, Poljak A, Crawford J, et al,. 2012. Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS One 7: e34078.
47. Sweet RA, Seltman H, Emanuel JE, et al,. 2012. Effect of Alzheimer's disease risk genes on trajectories of cognitive function in the cardiovascular health study. Am J Psychiatry 169: 954-962.
48. Tampi RR, Williamson D, Muralee S, et al,. 2011. Behavioral and psychological symptoms of dementia: part I-epidemiology, neurobiology, heritability, and evaluation. Clin Geriatrics 1: 1-6.
49. Thambisetty M, An Y, Kinsey A, et al,. 2012. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 59: 212-217.
50. Thambisetty M, Beason-Held LL, An Y, et al,. 2013. Alzheimer risk variant CLU and brain function during aging. Biol Psychiatry 73: 399-405.
51. Thambisetty M, Simmons A, Velayudhan L, et al,. 2010. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67: 739-748.
52. Trougakos IP, Poulakou M, Stathatos M, et al,. 2002. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol 37: 1175-1187.
53. Van der Mussele S, Le Bastard N, Vermeiren Y, et al,. 2013. Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. Int J Geriatr Psychiatry 28: 265-275.
54. Wadsworth LP, Lorius N, Donovan NJ, et al,. 2012. Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum. Dement Geriatr Cogn Disord 34: 96-111.
55. Walker MP, Ayre GA, Cummings JL, et al,. 2000. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 177: 252-256.
56. Wei L, Xue T, Wang J, et al,. 2009. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer. Int J Cancer 125: 791-806.
57. Won YS, Lee SJ, Yeo SG, et al,. 2012. Effects of female sex hormones on clusterin expression and paclitaxel resistance in endometrial cancer cell lines. Int J Med Sci 9: 86-92.
58. Xing YY, Yu JT, Cui WZ, et al,. 2012. Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease. J Alzheimers Dis 29: 515-519.
59. Yohannes AM, Baldwin RC, Connolly MJ,. 2008. Prevalence of depression and anxiety symptoms in elderly patients admitted in post-acute intermediate care. Int J Geriatr Psychiatry 23: 1141-1147.
60. Yu HR, Kuo HC, Huang EY, et al,. 2010. Plasma clusterin levels in predicting the occurrence of coronary artery lesions in patients with Kawasaki disease. Pediatr Cardiol 31: 1151-1156.